Table 2.

Adverse events in the study considered to be drug related

	CT‐707 dose
	300 mg b.i.d. (n = 2)		450 mg once a day (n = 7)		600 mg once a day (n = 4)		All patients (n = 13)
Preferred term	All grades, n (%)	Grade 3/4, n (%)	All grades, n (%)	Grade 3/4, n (%)	All grades, n (%)	Grade 3/4, n (%)	All grades, n (%)	Grade 3/4, n (%)
Diarrhea	2 (100)	0	7 (100)	0	3 (75)	1 (25)	12 (92)	1 (8)
Increased aspartate aminotransferase	1 (50)	0	6 (86)	0	1 (25)	0	8 (61)	0
Increased alanine aminotransferase	0	0	6 (86)	0	1 (25)	0	7 (54)	0
Nausea	2 (100)	0	2 (28)	0	1 (25)	0	5 (38)	0
Vomiting	0	0	3 (43)	0	1 (25)	0	4 (31)	0
Increased serum creatinine	1 (50)	0	3 (43)	0	0	0	4 (31)	0
Increased Glutamyltranspeptidase	1 (50)	0	3 (43)	1 (17)	0	0	4 (31)	1 (8)
Increased creatine kinase	1 (50)	0	2 (28)	0	0	0	3 (23)	0
Increased uric acid	0	0	2 (28)	0	1 (25)	0	3 (23)	0
Increased alkaline phosphatase	1 (50)	0	3 (43)	1 (17)	0	0	3 (23)	1 (8)
Loss of appetite	1 (50)	0	1 (14)	0	1 (25)	0	3 (23)	0
Stomach ache	0	0	2 (28)	0	0	0	2 (15)	0
Increased fasting blood glucose	0	0	1 (14)	0	0	0	1 (8)	0
Increased glycated hemoglobin	1 (50)	0	1 (14)	0	0	0	1 (8)	0
Increased total bile acids	0	0	0	0	1 (25)	0	1 (8)	0
Increased eosinophil absolute value	1 (50)	0	0	0	0	0	1 (8)	0